National Cancer Institute, 2026: NCI's account of the 1965 Rosenberg discovery and of NCI's role in developing platinum drugs, stating that platinum agents are prescribed for an estimated 10-20 percent of cancer patients.
Cisplatin and other similar platinum-based drugs were developed with National Cancer Institute (NCI) support. They are prescribed for an estimated 10 to 20 percent of all cancer patients.
HTML page, unpaginated
National Cancer Institute, 2026: NCI's account of the 1965 Rosenberg discovery and of NCI's role in developing platinum drugs, stating that platinum agents are prescribed for an estimated 10-20 percent of cancer patients. Funder/conflicts: n/a (NCI self-account, institutional interest). Comparator: n/a. This page credits Rosenberg and MSU with the discovery and NCI with development support; it does not mention MSU royalties or the Research Corporation patent assignment. Study type: other.
